Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds ...

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

THOU DOTH PORTEST — Protests are set to pop up around the Bay State this weekend, capping off a week of tension between the ...

Is a longevity pill on the horizon? Harvard Medical School professor David Sinclair certainly thinks so – while staring down ...

Ng reported personal fees from Bayer, Pfizer, CytomX, Jazz Pharmaceuticals, Revolution Medicines, Agenus, Johnson & Johnson, ...

The growing prevalence of uterine fibroids, especially among women of reproductive age, is fueling the demand for treatment devices. This surge is fu ...

The Veeva Commercial Summit 2025 highlighted the latest innovations connecting sales, marketing and medical — including Veeva AI.

Emerging markets remain a vital growth engine for Boston Scientific Corporation BSX, anchoring the company’s broader international strategy and long-term expansion plans. In the first quarter of 2025, ...

East Midlands-based biotechnology company N4 Pharma has formed a new senior leadership team featuring consultants in drug development and research, commercial strategy, and ...

Novo Nordisk signed a licensing deal with Septerna to co-develop oral therapies targeting GLP-1, GIP, and glucagon receptors for treating obesity, type II diabetes and other cardiometabolic diseases.

GSK is paying $1.2 billion upfront to Boston Pharmaceuticals for an experimental drug to treat MASH. Eli Lilly plans to expand Purdue University collaboration with up to a $250 million investment ...